King of Prussia, PA, 13 December, 2011 – Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced that it has been chosen by AlwaysOn as one of the Venture Summit Mid-Atlantic 100 winners. Inclusion in the Venture Summit Mid-Atlantic 100 signifies leadership amongst its peers and game-changing approaches and technologies that are likely to disrupt existing markets and entrenched players. Greenphire was specially selected by the AlwaysOn editorial team and industry experts spanning the globe based on a set of five criteria: innovation, market potential, commercialization, stakeholder value and media buzz.
Greenphire and the Venture Summit Mid-Atlantic 100 companies were honored at the IMPACT Venture Summit Mid-Atlantic event, November 29th and 30th, 2011, at the Ritz Carlton in Philadelphia, PA.
This two-day executive event featured CEO presentations and high-level debates on the most promising emerging technologies and new entrepreneurial opportunities on the East Coast. The Greater Philadelphia Alliance for Capital and Technologies (PACT) annual venture conference, IMPACT 2011, is the most established venture conference in the northeast. For over 20 years, IMPACT has been showcasing the best and most promising investment opportunities in the technology, life sciences and clean technology sectors.
“The Venture Summit Mid-Atlantic 100 winners are transforming the mid-Atlantic region’s technology community through innovation and creativity,” said Tony Perkins, founder and editor at AlwaysOn. “The companies represent some of the highest-growth opportunities in the mid-Atlantic private company marketplace across all industry sectors, including digital media and entertainment, on-demand computing as well as greentech and the life sciences.”
The Venture Summit Mid-Atlantic 100 winners were selected from among thousands of mid-Atlantic technology companies nominated by investors, bankers, journalists and greentech industry insiders. The AlwaysOn editorial team conducted a rigorous three-month selection process to finalize the 2011 list.
Greenphire is the leading provider of payment and communication technology solutions in the clinical trials industry. The firm was founded by Sam Whitaker and John Samar in 2008 with the vision of creating a globally scalable technology platform to allow pharmaceutical and medical device developers and clinical research sites to electronically deliver payments to investigators, vendors and trial participants. Since then, Greenphire’s technologies have been implemented to support over 60,000 clinical trial participants across 6,000 studies at 1,200 clinical trial sites.
"We're thrilled and honored to be included in AlwaysOn's Venture Summit Mid-Atlantic 100,” said Greenphire CEO Samuel Whitaker. “Greenphire's unique clinical payment solutions are a perfect fit with AlwaysOn's focus on technological innovation, and this recognition is extremely valuable as we continue to establish the Greenphire brand as the leader in developing cutting-edge clinical technology platforms."
A full list of all the Venture Summit Mid-Atlantic 100 winners can be found on the AlwaysOn website at:http://www.aonetwork.com/AOStory/Announcing-2011-Venture-Summit-Mid-Atlantic-100-Top-Private-Companies
About Greenphire
Greenphire’s clinical payment and communication solutions take a patient-centric and site-centric approach to driving data integrity and data completeness for sponsor, CRO, research university, and clinical research site clients. Greenphire’s web-based technologies are designed to improve the clinical experience for patients and sites, drive positive patient behavior, increase patient retention and compliance, and significantly reduce site and study team administration associated with patient payments and communication. Greenphire’s strategy is driven by the philosophy that empowered, satisfied patients and sites will deliver more consistent and better quality clinical data, which will in turn benefit both site coordinators and study teams. Learn more about Greenphire’s innovative clinical solutions at www.greenphire.com.
About AlwaysOn
AlwaysOn is the leading business media brand networking the Global Silicon Valley. AlwaysOn helped ignite the social media revolution in early 2003 when it launched the AlwaysOn network. In 2004, it became the first media brand to socially network its online readers and event attendees. AlwaysOn’s preeminent executive event series includes the Silicon Valley Innovation Summit, OnMedia, OnHollywood, Venture Summit Mid-Atlantic, OnDemand, Venture Summit Silicon Valley, OnMobile, and GoingGreen Silicon Valley. The AlwaysOn network and live event series continue to lead the industry by empowering its readers, event participants, sponsors, and advertisers like no other media brand.
For further information on Greenphire and its innovative solutions please email: sales@greenphire.com, call +1 215-609-4640 or visit www.greenphire.com.
For further press information please contact Celine Callender, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email greenphire@scottpr.com
Wednesday 14 December 2011
Friday 9 December 2011
Novozymes expands collaboration with Upperton Limited to offer customers new albumin conjugation solution
Conjugating Recombumin® Flex to drugs offers the opportunity to dramatically enhance patient lives and drive down healthcare costs.
NOTTINGHAM, UK – December 8, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes’ new Recombumin® Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients’ medical needs.
“Novozymes is delighted to unveil Recombumin Flex along with our new conjugation solution in partnership with Upperton Limited,” says Dave Mead, Business Development Director at Novozymes Biopharma. “Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider.”
By manipulating the interaction of albumin with its receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified albumins that bind with greater or lesser affinities, meaning a flexible half-life. Increasing the serum half-life of a drug may reduce the frequency of injections a patient receives or even reduce the amount of drug delivered, thereby significantly reducing toxic side-effects and increasing patient acceptance.
Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP and know-how around the albumin molecules themselves with Upperton’s rP-conjugate™ albumin conjugation chemistry knowledge, enables the companies to work closely with customers to design and implement the best chemical linking approach for their molecule. As a result, Novozymes can provide partners with a unique service from initial product concept through to in vivo testing for developing novel drugs.
Richard Johnson, founder and CEO of Upperton Limited, comments “By combining Novozymes’ and Upperton’s unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy.”
To learn more about Novozymes’ Recombumin Flex technology, please visit www.biopharma.novozymes.com.
To find out more about Upperton Limited, please visit www.upperton.com.
NOTTINGHAM, UK – December 8, 2011 – Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, has announced that it has expanded its partnership with Nottingham-based research and development company, Upperton Limited, to offer customers a new albumin conjugation solution. By linking drugs to Novozymes’ new Recombumin® Flex recombinant human albumin (rAlbumin), using conjugation, their pharmacokinetic and pharmacodynamic properties can be dramatically enhanced. As a result, manufacturers can benefit from the ability to tailor and control the half-life of drugs to fit patients’ medical needs.
“Novozymes is delighted to unveil Recombumin Flex along with our new conjugation solution in partnership with Upperton Limited,” says Dave Mead, Business Development Director at Novozymes Biopharma. “Novozymes has enjoyed a successful relationship with Upperton over the past 10 years and its expertise and experience in the conjugation of proteins, combined with our experience of protein engineering and production, will help customers to design drugs with tailored serum half-life and fewer side-effects. This will result in improved dosing regimes for the patient and a reduction in overall costs for the healthcare provider.”
By manipulating the interaction of albumin with its receptor, the neonatal Fc receptor (FcRn), Novozymes can produce modified albumins that bind with greater or lesser affinities, meaning a flexible half-life. Increasing the serum half-life of a drug may reduce the frequency of injections a patient receives or even reduce the amount of drug delivered, thereby significantly reducing toxic side-effects and increasing patient acceptance.
Upperton has demonstrated that proteins, peptides and small molecule APIs can be covalently attached to recombinant human albumin using a range of chemistries. Additionally, once drugs have been linked to the recombinant human albumin carrier, they exhibit dramatically improved pharmacokinetic and pharmacodynamic properties. Combining Novozymes' unique IP and know-how around the albumin molecules themselves with Upperton’s rP-conjugate™ albumin conjugation chemistry knowledge, enables the companies to work closely with customers to design and implement the best chemical linking approach for their molecule. As a result, Novozymes can provide partners with a unique service from initial product concept through to in vivo testing for developing novel drugs.
Richard Johnson, founder and CEO of Upperton Limited, comments “By combining Novozymes’ and Upperton’s unmatched expertise in our respective fields, we have developed a solution that solves industry challenges by enabling a tunable half-life that offers control and flexibility and has the potential to improve overall treatment efficacy.”
To learn more about Novozymes’ Recombumin Flex technology, please visit www.biopharma.novozymes.com.
To find out more about Upperton Limited, please visit www.upperton.com.
SmartKem Expands International Presence with Appointment of Japanese Representative
(9 December, 2011) – SmartKem Limited, the developer of high performance, printable organic semiconductor materials for flexible electronics, today announced the appointment of a Japanese representative, Dr. Yutaka Hirai of Business Link Japan. This partnership, combining SmartKem’s niche scientific expertise and the consultation services of Dr. Hirai, will support SmartKem’s growth in the TFT and electronics display market. The expansion will enable the company to target the complete supply chain in Japan, from chemical suppliers to printing specialists and electronics manufacturers. With a strong heritage in the development of organic semiconductor technology for TFT display applications, SmartKem will deliver customised ink formulations that are designed to enable the manufacture of lightweight, ultra-thin and rugged flat panel displays as used in smartphones, laptops, tablet PCs and TV screens.
Based in Tokyo, Japan, Dr. Hirai brings to the role extensive high level technology experience, having worked for large organizations such as Canon Inc. at senior management and Director level. Dr. Hirai has specialist expertise in semiconductor materials and devices for applications such as displays, sensors, solar cells and fuel cells. Dr. Hirai will be responsible for ensuring that SmartKem’s world class organic semiconductor materials are directed at leading Japanese organisations who are involved in the development and manufacture of flexible, lightweight and large-area printed electronics. Priority will be given to market-driven applications such as EPD, OLED and HD LCD display industries. Asia is the home of electronic device manufacturing and provides an exciting market potential for SmartKem’s technology. The appointment of a highly respected representative in Japan marks the starting point of SmartKem’s Asian strategy.
“I am very excited to have the opportunity to represent SmartKem in Japan. The future of lightweight and flexible electronics will be driven by pioneering advances in material technology that will enable limitless applications comments Dr. Hirai. SmartKem is leading the development of these materials and it is with great pride that I will represent the company in the Japanese market with ground-breaking organic semiconductor solutions.”
"The global market for ultra-thin, lightweight printable electronics is growing rapidly and is estimated to reach $45 billion by 2016. Being a fast evolving industrial market, Japan is expected to play a key role in new developments, offering exceptional growth opportunities for forward-looking companies such as SmartKem adds Steve Kelly, CEO of SmartKem. Dr. Hirai is highly respected in the electronics industry and has impressive credentials within our target market sectors. We are confident that he will exceed our expectations and help us achieve our goal of becoming the leading independent provider of organic semiconductor solutions for TFT displays.”
SmartKem was advised by Peter Bacon of Electronics Link Asia on this project.
For more information on SmartKem and its innovative materials, please call 01745 535190, email enquiries@smartkem.com or visit www.smartkem.com
-ENDS-
About SmartKem
SmartKem is a high tech enterprise developing an exciting new technology platform focusing on high performance/high value organic semiconductor materials that can be ‘printed’ to form electronic circuits onto lightweight, rugged and low cost polymer films. Based in the world class Optic Technium centre, North Wales, SmartKem’s main objective is to respond to the demand for low cost, low weight, low energy, rugged electronics. The SmartKem team has proven expertise and experience in the fields of organic semiconductors, specialist ink-technology and printable transistors and was a recent winner of the inaugural Oxford Venturefest gold award for ‘British Technology Innovation of the Year’.
Based in Tokyo, Japan, Dr. Hirai brings to the role extensive high level technology experience, having worked for large organizations such as Canon Inc. at senior management and Director level. Dr. Hirai has specialist expertise in semiconductor materials and devices for applications such as displays, sensors, solar cells and fuel cells. Dr. Hirai will be responsible for ensuring that SmartKem’s world class organic semiconductor materials are directed at leading Japanese organisations who are involved in the development and manufacture of flexible, lightweight and large-area printed electronics. Priority will be given to market-driven applications such as EPD, OLED and HD LCD display industries. Asia is the home of electronic device manufacturing and provides an exciting market potential for SmartKem’s technology. The appointment of a highly respected representative in Japan marks the starting point of SmartKem’s Asian strategy.
“I am very excited to have the opportunity to represent SmartKem in Japan. The future of lightweight and flexible electronics will be driven by pioneering advances in material technology that will enable limitless applications comments Dr. Hirai. SmartKem is leading the development of these materials and it is with great pride that I will represent the company in the Japanese market with ground-breaking organic semiconductor solutions.”
"The global market for ultra-thin, lightweight printable electronics is growing rapidly and is estimated to reach $45 billion by 2016. Being a fast evolving industrial market, Japan is expected to play a key role in new developments, offering exceptional growth opportunities for forward-looking companies such as SmartKem adds Steve Kelly, CEO of SmartKem. Dr. Hirai is highly respected in the electronics industry and has impressive credentials within our target market sectors. We are confident that he will exceed our expectations and help us achieve our goal of becoming the leading independent provider of organic semiconductor solutions for TFT displays.”
SmartKem was advised by Peter Bacon of Electronics Link Asia on this project.
For more information on SmartKem and its innovative materials, please call 01745 535190, email enquiries@smartkem.com or visit www.smartkem.com
-ENDS-
About SmartKem
SmartKem is a high tech enterprise developing an exciting new technology platform focusing on high performance/high value organic semiconductor materials that can be ‘printed’ to form electronic circuits onto lightweight, rugged and low cost polymer films. Based in the world class Optic Technium centre, North Wales, SmartKem’s main objective is to respond to the demand for low cost, low weight, low energy, rugged electronics. The SmartKem team has proven expertise and experience in the fields of organic semiconductors, specialist ink-technology and printable transistors and was a recent winner of the inaugural Oxford Venturefest gold award for ‘British Technology Innovation of the Year’.
Subscribe to:
Posts (Atom)